Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Patient survival and maintenance dialysis

OVERVIEW

Although maintenance dialysis prevents death from uremia, patient survival remains an important issue. Once renal replacement therapy is initiated, the range of the expected remaining life span in the United States Renal Data System (USRDS) report was approximately 8 years (varies with race) for dialysis patients aged 40 to 44 and approximately 4.5 years for those 60 to 64 years of age [1]. These values in older patients are only slightly better than those in patients with lung cancer and are much worse than the general population (which is 30 to 40 years for those aged 40 to 44 and 17 to 22 years for individuals aged 60 to 64). Despite this, some evidence suggests that mortality rates among incident dialysis patients have decreased over the last few years, suggesting that improvements in therapy may provide beneficial results [1].

It is well established that inadequate dialysis is a contributor to lower overall survival. This has important implications since more intensive dialysis, particularly above a certain threshold value, may improve survival, possibly as with nocturnal hemodialysis.

Additional factors associated with the dialysis procedure may also correlate with decreased survival. As examples:

Dialysis vintage is associated with an enhanced risk of death, with each year of dialysis treatment increasing the risk of death by approximately 6 percent [2].

Potassium levels <4.0 or >5.6 mEq/L are associated with increased mortality in hemodialysis patients, compared with serum levels between 4.6 and 5.3 mEq/L [3].

                            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2014. | This topic last updated: Jan 6, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010; 55:S1.
  2. Chertow GM, Johansen KL, Lew N, et al. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 2000; 57:1176.
  3. Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007; 2:999.
  4. Szczech LA, Klassen PS, Chua B, et al. Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units. Kidney Int 2006; 69:2094.
  5. Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med 1999; 341:1653.
  6. Levinsky NG. Quality and equity in dialysis and renal transplantation. N Engl J Med 1999; 341:1691.
  7. Irvin RA. Quality of care differences by ownership in United States renal dialysis facilities. ASAIO J 2000; 46:775.
  8. Devereaux PJ, Schünemann HJ, Ravindran N, et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA 2002; 288:2449.
  9. Harley KT, Streja E, Rhee CM, et al. Nephrologist caseload and hemodialysis patient survival in an urban cohort. J Am Soc Nephrol 2013; 24:1678.
  10. Yan G, Norris KC, Xin W, et al. Facility size, race and ethnicity, and mortality for in-center hemodialysis. J Am Soc Nephrol 2013; 24:2062.
  11. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. Causes of death in dialysis patients: racial and gender differences. J Am Soc Nephrol 1994; 5:1231.
  12. Cohen LM, McCue JD, Germain M, Kjellstrand CM. Dialysis discontinuation. A 'good' death? Arch Intern Med 1995; 155:42.
  13. Wallen MD, Radhakrishnan J, Appel G, et al. An analysis of cardiac mortality in patients with new-onset end-stage renal disease in New York State. Clin Nephrol 2001; 55:101.
  14. O'Seaghdha CM, Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int 2005; 25:534.
  15. Introduction and summary. Proceedings from the Morbidity, Mortality and Prescription of Dialysis Symposium, Dallas, Tx, September 15 to 17, 1989. Am J Kidney Dis 1990; 15:375.
  16. Collins AJ, Hanson G, Umen A, et al. Changing risk factor demographics in end-stage renal disease patients entering hemodialysis and the impact on long-term mortality. Am J Kidney Dis 1990; 15:422.
  17. Mailloux LU, Napolitano B, Bellucci AG, et al. The impact of co-morbid risk factors at the start of dialysis upon the survival of ESRD patients. ASAIO J 1996; 42:164.
  18. Merkus MP, Jager KJ, Dekker FW, et al. Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. Am J Kidney Dis 2000; 35:69.
  19. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14:3270.
  20. Centers for Medicare and Medicaid Services, Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48:S1.
  21. Miskulin D, Bragg-Gresham J, Gillespie BW, et al. Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:1818.
  22. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380.
  23. Parfrey PS. Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 1993; 21:77.
  24. Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 1991; 2:2.
  25. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17:1085.
  26. Beddhu S, Zeidel ML, Saul M, et al. The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis. Am J Med 2002; 112:696.
  27. Miskulin DC, Meyer KB, Martin AA, et al. Comorbidity and its change predict survival in incident dialysis patients. Am J Kidney Dis 2003; 41:149.
  28. Mailloux LU, Bellucci AG, Napolitano B, et al. Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival. Clin Nephrol 1994; 42:127.
  29. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.
  30. Hirsch DJ, West ML, Cohen AD, Jindal KK. Experience with not offering dialysis to patients with a poor prognosis. Am J Kidney Dis 1994; 23:463.
  31. Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007; 146:177.
  32. van Dijk PC, Jager KJ, de Charro F, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16:1120.
  33. Goodkin DA, Young EW, Kurokawa K, et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44:16.
  34. Yoshino M, Kuhlmann MK, Kotanko P, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006; 17:3510.
  35. van Dijk PC, Zwinderman AH, Dekker FW, et al. Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe. Kidney Int 2007; 71:53.
  36. Wong JS, Port FK, Hulbert-Shearon TE, et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int 1999; 55:2515.
  37. Tanna MM, Vonesh EF, Korbet SM. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting. Am J Kidney Dis 2000; 36:1175.
  38. Eisenstein EL, Sun JL, Anstrom KJ, et al. Do income level and race influence survival in patients receiving hemodialysis? Am J Med 2009; 122:170.
  39. Bleyer AJ, Tell GS, Evans GW, et al. Survival of patients undergoing renal replacement therapy in one center with special emphasis on racial differences. Am J Kidney Dis 1996; 28:72.
  40. Mesler DE, McCarthy EP, Byrne-Logan S, et al. Does the survival advantage of nonwhite dialysis patients persist after case mix adjustment? Am J Med 1999; 106:300.
  41. Robinson BM, Joffe MM, Pisoni RL, et al. Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2006; 17:2910.
  42. Kucirka LM, Grams ME, Lessler J, et al. Association of race and age with survival among patients undergoing dialysis. JAMA 2011; 306:620.
  43. Mehrotra R, Kermah D, Fried L, et al. Racial differences in mortality among those with CKD. J Am Soc Nephrol 2008; 19:1403.
  44. Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19:1379.
  45. Kimmel PL, Peterson RA, Weihs KL, et al. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int 1998; 54:245.
  46. Kimmel PL, Fwu CW, Eggers PW. Segregation, income disparities, and survival in hemodialysis patients. J Am Soc Nephrol 2013; 24:293.
  47. Chung SH, Lindholm B, Lee HB. Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. Perit Dial Int 2000; 20:19.
  48. Mc Causland FR, Waikar SS, Brunelli SM. Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney Int 2012; 82:204.
  49. Rambod M, Tolouian R. Dietary sodium and clinical outcome in hemodialysis: where do we stand and what is next? Kidney Int 2012; 82:130.
  50. Benz RL, Pressman MR, Hovick ET, Peterson DD. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis 2000; 35:1052.
  51. Unruh ML, Buysse DJ, Dew MA, et al. Sleep quality and its correlates in the first year of dialysis. Clin J Am Soc Nephrol 2006; 1:802.
  52. McClellan WM, Wasse H, McClellan AC, et al. Treatment center and geographic variability in pre-ESRD care associate with increased mortality. J Am Soc Nephrol 2009; 20:1078.
  53. Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18:3164.
  54. Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3:133.
  55. Brunelli SM, Joffe MM, Israni RK, et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:777.
  56. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70:1358.
  57. Beaubrun AC, Kilpatrick RD, Freburger JK, et al. Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients. J Am Soc Nephrol 2013; 24:1461.
  58. Desmet C, Beguin C, Swine C, et al. Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. Am J Kidney Dis 2005; 45:148.
  59. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 2004; 44:672.
  60. Johansen KL, Chertow GM, Jin C, Kutner NG. Significance of frailty among dialysis patients. J Am Soc Nephrol 2007; 18:2960.
  61. Unruh ML, Evans IV, Fink NE, et al. Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients. Am J Kidney Dis 2005; 46:1107.
  62. O'Hare AM, Tawney K, Bacchetti P, Johansen KL. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis 2003; 41:447.
  63. Stack AG, Molony DA, Rives T, et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45:690.
  64. Matsuzawa R, Matsunaga A, Wang G, et al. Habitual physical activity measured by accelerometer and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2012; 7:2010.
  65. Johansen KL, Kaysen GA, Dalrymple LS, et al. Association of physical activity with survival among ambulatory patients on dialysis: the Comprehensive Dialysis Study. Clin J Am Soc Nephrol 2013; 8:248.
  66. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20:872.
  67. Kshirsagar AV, Craig RG, Moss KL, et al. Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int 2009; 75:746.
  68. Ramirez SP, Albert JM, Blayney MJ, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20:1094.
  69. Lin JL, Lin-Tan DT, Hsu CW, et al. Association of blood lead levels with mortality in patients on maintenance hemodialysis. Am J Med 2011; 124:350.
  70. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005; 45:A5.
  71. Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982; 22:304.
  72. Held PJ, Levin NW, Bovbjerg RR, et al. Mortality and duration of hemodialysis treatment. JAMA 1991; 265:871.
  73. Woods JD, Port FK, Stannard D, et al. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. Kidney Int 1996; 49:1464.
  74. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28:526.
  75. Laird NM, Berkey CS, Lowrie EG. Modeling success or failure of dialysis therapy: the National Cooperative Dialysis Study. Kidney Int Suppl 1983; :S101.
  76. Parker TF, Laird NM, Lowrie EG. Comparison of the study groups in the National Cooperative Dialysis Study and a description of morbidity, mortality, and patient withdrawal. Kidney Int Suppl 1983; :S42.
  77. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994; 23:272.
  78. Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.
  79. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661.
  80. Parker TF 3rd, Husni L, Huang W, et al. Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994; 23:670.
  81. Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50:550.
  82. McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol 1998; 9:1940.
  83. Chertow GM, Owen WF, Lazarus JM, et al. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999; 56:1872.
  84. Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13:1061.
  85. Gotch FA, Levin NW, Port FK, et al. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis 1997; 30:1.
  86. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.
  87. Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003; 14:1863.
  88. Wolfe RA, Hulbert-Shearon TE, Ashby VB, et al. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis 2005; 45:127.
  89. Paniagua R, Amato D, Vonesh E, et al. Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial. Kidney Int 2005; 67:1093.
  90. Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:645.
  91. Cheung AK, Greene T. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:462.
  92. Alonso A, Lau J, Jaber BL. Biocompatible hemodialysis membranes for acute renal failure. Cochrane Database Syst Rev 2005; :CD005283.
  93. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006; 69:1229.
  94. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69:1222.
  95. Tentori F, Zhang J, Li Y, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012; 27:4180.
  96. Flythe JE, Curhan GC, Brunelli SM. Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int 2013; 83:104.
  97. Sharp J, Wild MR, Gumley AI. A systematic review of psychological interventions for the treatment of nonadherence to fluid-intake restrictions in people receiving hemodialysis. Am J Kidney Dis 2005; 45:15.
  98. Pillon L, Piccoli A, Lowrie EG, et al. Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Kidney Int 2004; 66:1266.
  99. Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15:1061.
  100. Reddan DN, Szczech LA, Hasselblad V, et al. Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 2005; 16:2162.
  101. Hur E, Usta M, Toz H, et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis 2013; 61:957.
  102. Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365:1099.
  103. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.
  104. Goldwasser P, Mittman N, Antignani A, et al. Predictors of mortality in hemodialysis patients. J Am Soc Nephrol 1993; 3:1613.
  105. Dwyer JT, Larive B, Leung J, et al. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney Int 2005; 68:1766.
  106. Rocco MV, Jordan JR, Burkart JM. The efficacy number as a predictor of morbidity and mortality in peritoneal dialysis patients. J Am Soc Nephrol 1993; 4:1184.
  107. Chung SH, Lindholm B, Lee HB. Is malnutrition an independent predictor of mortality in peritoneal dialysis patients? Nephrol Dial Transplant 2003; 18:2134.
  108. Ramkumar N, Pappas LM, Beddhu S. Effect of body size and body composition on survival in peritoneal dialysis patients. Perit Dial Int 2005; 25:461.
  109. Kakiya R, Shoji T, Tsujimoto Y, et al. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 2006; 70:549.
  110. Keshaviah PR, Nolph KD, Moore HL, et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994; 4:1475.
  111. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56:1136.
  112. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997; 29:658.
  113. Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:1635.
  114. Fleischmann E, Teal N, Dudley J, et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55:1560.
  115. Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16:2386.
  116. Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis 2003; 41:925.
  117. Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among "large" ESRD patients in the United States. Kidney Int 2004; 65:2398.
  118. Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80:324.
  119. Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14:2366.
  120. de Mutsert R, Snijder MB, van der Sman-de Beer F, et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007; 18:967.
  121. Hakim RM, Lowrie E. Obesity and mortality in ESRD: is it good to be fat? Kidney Int 1999; 55:1580.
  122. Hoogeveen EK, Halbesma N, Rothman KJ, et al. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 2012; 7:280.
  123. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 2003; 14:2894.
  124. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208.
  125. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67:1179.
  126. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16:1788.
  127. Noordzij M, Korevaar JC, Boeschoten EW, et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46:925.
  128. Noordzij M, Korevaar JC, Bos WJ, et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006; 21:2513.
  129. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52:519.
  130. Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16:386.
  131. Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38:1351.
  132. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115.
  133. Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24:1506.
  134. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70:351.
  135. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70:771.
  136. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584.
  137. Seiler S, Reichart B, Roth D, et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25:3983.
  138. McDiarmid SV, Hall TR, Grant EG, et al. Failure of duplex sonography to diagnose hepatic artery thrombosis in a high-risk group of pediatric liver transplant recipients. J Pediatr Surg 1991; 26:710.
  139. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22:956.
  140. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152:640.
  141. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19:2193.
  142. Drechsler C, Verduijn M, Pilz S, et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011; 6:1752.
  143. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med 2006; 145:512.
  144. Plantinga LC, Fink NE, Jaar BG, et al. Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study. BMC Health Serv Res 2007; 7:5.
  145. Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007; 18:2377.
  146. Wingard RL, Pupim LB, Krishnan M, et al. Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. Clin J Am Soc Nephrol 2007; 2:1170.
  147. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1423.
  148. Slinin Y, Guo H, Gilbertson DT, et al. Meeting KDOQI guideline goals at hemodialysis initiation and survival during the first year. Clin J Am Soc Nephrol 2010; 5:1574.
  149. Huisman RM, Nieuwenhuizen MG, Th de Charro F. Patient-related and centre-related factors influencing technique survival of peritoneal dialysis in The Netherlands. Nephrol Dial Transplant 2002; 17:1655.
  150. Schaubel DE, Blake PG, Fenton SS. Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis. Kidney Int 2001; 60:1517.
  151. Mehrotra R, Khawar O, Duong U, et al. Ownership patterns of dialysis units and peritoneal dialysis in the United States: utilization and outcomes. Am J Kidney Dis 2009; 54:289.
  152. Hakim RM, Held PJ, Stannard DC, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50:566.
  153. Bloembergen WE, Stannard DC, Port FK, et al. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996; 50:557.